|
KMID : 0942820100090020067
|
|
Journal of Korean Brain Tumor Society
2010 Volume.9 No. 2 p.67 ~ p.73
|
|
|
A Preliminary Study for Evaluability and Compatibility
|
|
Kim In-Kyeong
Yoo Heon
Shin Sang-Hoon
Youn Sang-Min
Rhee Chang-Hun
Lee Seung-Hoon
Gwak Ho-Shin
|
|
|
Abstract
|
|
|
Purpose: To evaluate 1) if brain tumor samples are evaluable for Histoculture Drug Response Assay(HDRA), 2) applied drug concentration can show individualized chemosensitivity, 3) difference among tumor types or histological grades.
Methods: From 2002 to 2008, sixty-seven patients with histologically proven brain tumor including glioma, metastasis and others were operated and the tumor samples were examined their chemosensitivity to 10 chosen chemotherapeutic drugs by HDRA. An inhibition rate(IR) was defined as percentage of inhibited tumor tissue growth by a drug relative to control.
Results: The spectrum of sensitive drug among individual patients and the inhibition rate of each drug were varied and ranged widely. The mean number of tested drug was 7.9(range 6.9-8.6) and the mean number of sensitive drug was 2.8(range 2.2-4.1). The overall evaluability was 58/65(89%). The evaluability between tumor groups of low grade glioma, grade III glioma, grade IV glioma, metastatic brain tumor, and other brain tumors was not significantly different. The inhibition rate to all brain tumor types ranged from 19.9%(PCB) to 34.8%(CDDP). Cut-off value of 30% showed acceptable range of sensitivity results in all tested drugs except VP-16 and PCB. Sensitivity in terms of both mean IR and sensitive rate(number of sensitive results per tested drugs) of low grade gliomas showed a tendency to be higher than grade III and IV gliomas(0.05)
Conclusion：HDRA for brain tumor was feasible method to evaluate the individual patient’s chemosensitivity to certain chemotherapeutic drugs.
|
|
|
KEYWORD
|
|
|
Anticancer drug sensitivity tests, Brain neoplasm, Chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|